<!doctype html><html lang=en><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1,maximum-scale=1"><meta name=description content="Our plan is to finish the pre-IPO by the end of this year and move to IPO early next year, he added. In terms of listing venues, we are actually keeping our options open in various markets. The US is one of the markets we are considering in addition to Hong Kong."><meta name=generator content="Hugo 0.98.0"><meta name=robots content="index,follow,noarchive"><title>Chinese biotech firm boosts funding, plans IPO next to catch European rivals in cancer therapy marke &#183;</title><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/pure/1.0.0/pure-min.css><!--[if lte IE 8]><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/pure/1.0.0/grids-responsive-old-ie-min.css><![endif]--><!--[if gt IE 8]><!--><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/pure/1.0.0/grids-responsive-min.css><!--<![endif]--><!--[if lte IE 8]><link rel=stylesheet href=https://assets.cdnweb.info/hugo/blackburn/css/side-menu-old-ie.css><![endif]--><!--[if gt IE 8]><!--><link rel=stylesheet href=https://assets.cdnweb.info/hugo/blackburn/css/side-menu.css><!--<![endif]--><link rel=stylesheet href=https://assets.cdnweb.info/hugo/blackburn/css/blackburn.css><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.2/css/all.min.css><link rel=preconnect href=https://fonts.gstatic.com><link href="https://fonts.googleapis.com/css2?family=Raleway&display=swap" rel=stylesheet type=text/css><script async src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.9/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
<link rel=stylesheet href=//cdnjs.cloudflare.com/ajax/libs/highlight.js/10.6.0/styles/androidstudio.min.css><script async src=//cdnjs.cloudflare.com/ajax/libs/highlight.js/10.6.0/highlight.min.js></script>
<script>hljs.initHighlightingOnLoad()</script><link rel="shortcut icon" href=./img/favicon.ico type=image/x-icon></head><body><div id=layout><a href=#menu id=menuLink class=menu-link><span></span></a><div id=menu><a class="pure-menu-heading brand" href=./index.html>BlinkBlog</a><div class=pure-menu><ul class=pure-menu-list><li class=pure-menu-item><a class=pure-menu-link href=./index.html><i class="fa fa-home fa-fw"></i>Home</a></li><li class=pure-menu-item><a class=pure-menu-link href=./post/index.html><i class="fa fa-list fa-fw"></i>Posts</a></li><li class=pure-menu-item><a class=pure-menu-link href=./sitemap.xml><i class="fa fa-user fa-fw"></i>Sitemap</a></li><li class=pure-menu-item><a class=pure-menu-link href=./index.xml><i class="fa fa-phone fa-fw"></i>RSS</a></li></ul></div><div class="pure-menu social"><ul class=pure-menu-list></ul></div><div><div class=small-print><small>&copy; 2022. All rights reserved.</small></div><div class=small-print><small>Built with&nbsp;<a href=https://gohugo.io/ target=_blank>Hugo</a></small>
<small>Theme&nbsp;<a href=https://github.com/yoshiharuyamashita/blackburn target=_blank>Blackburn</a></small></div></div></div><div id=main><div class=header><h1>Chinese biotech firm boosts funding, plans IPO next to catch European rivals in cancer therapy marke</h1><h2>Our plan is to finish the pre-IPO by the end of this year and move to IPO early next year, he added. In terms of listing venues, we are actually keeping our options open in various markets. The US is one of the markets we are considering in addition to Hong Kong.</h2></div><div class=content><div class=post-meta><div><i class="fa fa-calendar fa-fw"></i>
<time>11 May 2024, 00:00</time></div></div><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">“Our plan is to finish the pre-IPO by the end of this year and move to IPO early next year,” he added. In terms of listing venues, “we are actually keeping our options open in various markets. The US is one of the markets we are considering in addition to Hong Kong.”</p><img style=margin:auto;display:block;text-align:center;max-width:100%;height:auto src=https://cdn.statically.io/img/cdn.i-scmp.com/sites/default/files/d8/images/canvas/2021/03/22/bbe4cfc8-05e0-4a26-805d-ba8c6a33a718_aa48465f.jpg><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">EpimAb’s Series C financing round was co-led by China Merchants Bank International and Mirae Asset Financial Group of South Korea. Other backers included mainland private equity firm Hony Capital and Boston-based hedge fund Cormorant Asset Management. Adrian Cheng, who runs developer Hong Kong-listed New World Development, is also an investor.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Appetite among investors in this segment is abundant as bispecific antibody, a new type of antibody-based therapy, is seen as a potential next big advancement in oncology. The global bispecific antibody market – not just limited to cancer treatment – is expected to reach US$12 billion by 2026, according to a report published by Kuick Research in September.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Bispecific antibody is an artificial protein that can simultaneously bind to two different types of antigen, working by directly engaging immune cells to attack tumour cells.</p><img data-qa=BaseImage-handleRenderImage-StyledImage src=https://cdn.statically.io/img/cdn.i-scmp.com/sites/default/files/styles/wide_landscape/public/d8/video/thumbnail/2020/05/01/cleanthumbnail.jpg style=margin:auto;display:block;text-align:center><p data-qa=SCMPYoutubeVideoPreview-PreviewDuration class="css-dkee4u eaw92su1">03:06</p><p data-qa=SCMPYoutubeVideoPreview-PreviewTitle class="css-1ajvbe4 eaw92su2">Chinese firm ready to make 100 million Coronavirus vaccine doses if trials are successful</p><p>Chinese firm ready to make 100 million Coronavirus vaccine doses if trials are successful</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">“In the cancer environment, immune cells cannot recognise the cancer cells,” Wu explained. “Bispecific antibodies ensure the immune cells can target and find the cancerous cells and kill them very quickly. It is like a person with two hands grabbing two ends and facilitating this killing process.”</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Wu, who received his doctorate from the University of Georgia and postdoctoral training at Harvard Medical School, founded EpimAb in 2015. He was formerly chief scientific officer at Shanghai CP Guojian Pharmaceutical from 2013 before setting out on his own venture.</p><img style=margin:auto;display:block;text-align:center;max-width:100%;height:auto src=https://cdn.statically.io/img/cdn.i-scmp.com/sites/default/files/styles/wide_landscape/public/d8/video/thumbnail/2020/05/01/cleanthumbnail.jpg><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">EpimAb is one of only a handful of biotech companies in China with a proprietary technology.&nbsp;Its FIT-Ig, or Fabs-In-Tandem Immunoglobulin, technology&nbsp;can be used to develop products that generate bispecific molecules with antibody-like properties.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">The company is not alone in bolstering its finances. Dutch group Merus raised US$120 million from a stock placement in January, while Affimed of Germany collected US$115 million in the same month. Their shares have risen 31 per cent and 43 per cent respectively this year, according to Bloomberg data.</p>Hong Kong’s stock exchange <a class="euc41pk0 e13op9j60 e1qbu6wp1 css-jgjyn2 ef1hf1w0" href=# data-qa=BaseLink-renderAnchor-StyledAnchor><span data-qa=Component-Text class="css-0 e1qbu6wp0">hosted 14 biotechnology IPOs in 2020</span></a> versus nine in 2019. In total, 22 health care firms raised US$12.7 billion, accounting for a quarter of IPO proceeds in Hong Kong, according to KPMG. The November US$592 million listing of autoimmune diseases drugs developer RemeGen topped the list.<p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Wu said EpimAb plans to use the US$120 million Series C proceeds to fund the ongoing development of its three clinical assets, namely EMB-01, EMB-02 and EMB-06, and to expand its pipeline of novel bispecific antibodies and other biologics.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Its leading candidate EMB-01 is designed to simultaneously target EGFR and cMET, two receptors widely expressed on multiple cell types, and their deregulation or mutation can lead to cancer, including lung cancer. The clinical asset is currently progressing to phase two clinical studies in both China and the US, Wu added.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Currently, there are two bispecific antibodies being commercially marketed globally. They are US-based Amgen’s Blincyto for acute lymphoblastic leukaemia, and Roche’s Hemlibra for haemophilia.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">RemeGen, the Yantai, Shandong province-based biotech firm, received China’s approval last month for its RC18 product for systemic lupus erythematosus. At HK$100, its shares have almost doubled from the IPO level of HK$52.10.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">“Our aspiration is to become a global leader in bispecific drug development,” said David Gu Xinyi, chief financial officer of EpimAb.</p><p class=postsid style=color:rgba(255,0,0,0)>ncG1vNJzZmivp6x7tK%2FMqWWcp51kr7a%2FyKecrKtfmLWqusBmma6rmaOytL%2BOmqmtoZOhsnB%2FkGttbW5oZLCptc2eqp5lkp68tbHCoWSfoaKieqO7zqyrrGWWqrultc2gZKmkkaPAbrXPqGSnnaipeqSt05yf</p><h4><i class="fas fa-share-alt" aria-hidden=true></i>&nbsp;Share!</h4><ul class=share-buttons><li><a href="https://www.facebook.com/sharer/sharer.php?u=%2fchinese-biotech-firm-boosts-funding-plans-ipo-next-catch.html" target=_blank title="Share on Facebook"><i class="fab fa-facebook" aria-hidden=true></i><span class=sr-only>Share on Facebook</span></a></li>&nbsp;&nbsp;&nbsp;<li><a href="https://twitter.com/intent/tweet?source=%2fchinese-biotech-firm-boosts-funding-plans-ipo-next-catch.html" target=_blank title=Tweet><i class="fab fa-twitter" aria-hidden=true></i><span class=sr-only>Tweet</span></a></li>&nbsp;&nbsp;&nbsp;<li><a href="https://plus.google.com/share?url=%2fchinese-biotech-firm-boosts-funding-plans-ipo-next-catch.html" target=_blank title="Share on Google+"><i class="fab fa-google-plus" aria-hidden=true></i><span class=sr-only>Share on Google+</span></a></li>&nbsp;&nbsp;&nbsp;<li><a href="http://www.tumblr.com/share?v=3&u=%2fchinese-biotech-firm-boosts-funding-plans-ipo-next-catch.html" target=_blank title="Post to Tumblr"><i class="fab fa-tumblr" aria-hidden=true></i><span class=sr-only>Post to Tumblr</span></a></li>&nbsp;&nbsp;&nbsp;<li><a href="http://pinterest.com/pin/create/button/?url=%2fchinese-biotech-firm-boosts-funding-plans-ipo-next-catch.html" target=_blank title="Pin it"><i class="fab fa-pinterest-p" aria-hidden=true></i><span class=sr-only>Pin it</span></a></li>&nbsp;&nbsp;&nbsp;<li><a href="http://www.reddit.com/submit?url=%2fchinese-biotech-firm-boosts-funding-plans-ipo-next-catch.html" target=_blank title="Submit to Reddit"><i class="fab fa-reddit-alien" aria-hidden=true></i><span class=sr-only>Submit to Reddit</span></a></li></ul><style>ul.share-buttons{list-style:none;padding:0}ul.share-buttons li{display:inline}ul.share-buttons .sr-only{position:absolute;clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);padding:0;border:0;height:1px;width:1px;overflow:hidden}</style><div class="prev-next-post pure-g"><div class=pure-u-1-24 style=text-align:left><a href=./rey-felipe-vi-sube-primera-vez-podio-copa-html.html><i class="fa fa-chevron-left"></i></a></div><div class=pure-u-10-24><nav class=prev><a href=./rey-felipe-vi-sube-primera-vez-podio-copa-html.html>Felipe VI sube por primera vez al podio en la Copa del Rey MAPFRE</a></nav></div><div class=pure-u-2-24>&nbsp;</div><div class=pure-u-10-24><nav class=next><a href=./camila-morrone-ugg-aww-yeah-sandals-7483809.html>Camila Morrone Just Wore Uggs Aww Yeah Sandals at Coachella</a></nav></div><div class=pure-u-1-24 style=text-align:right><a href=./camila-morrone-ugg-aww-yeah-sandals-7483809.html><i class="fa fa-chevron-right"></i></a></div></div></div></div></div><script src=https://assets.cdnweb.info/hugo/blackburn/js/ui.js></script>
<script src=https://assets.cdnweb.info/hugo/blackburn/js/menus.js></script>
<script src=./js/math-code.js></script>
<script async src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.7/MathJax.js?config=TeX-MML-AM_CHTML"></script>
<script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://js.zainuddin.my.id/floating.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://js.zainuddin.my.id/tracking_server_6.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script>var _paq=window._paq=window._paq||[];_paq.push(["trackPageView"]),_paq.push(["enableLinkTracking"]),function(){e="//analytics.cdnweb.info/",_paq.push(["setTrackerUrl",e+"matomo.php"]),_paq.push(["setSiteId","1"]);var e,n=document,t=n.createElement("script"),s=n.getElementsByTagName("script")[0];t.async=!0,t.src=e+"matomo.js",s.parentNode.insertBefore(t,s)}()</script></body></html>